Netherlands: Bos joins Forbion’s Growth Fund investment team

European dedicated life sciences venture capital firm, Forbion, has appointed Jasper Bos to its investment team as general partner for the firm’s Growth Fund. Before joining Forbion, Bos was senior vice president and managing director at M Ventures, the venture arm of Merck, which he joined in 2009.

At M Ventures, he led a team of 21 investment professionals and a fund of €400m (US$487.3m) invested in over 50 portfolio companies spanning biotech, life sciences tools, and tech companies with investment activities ranging from seed-stage to cross-over and IPO.

“Bos’ scientific and financial experience will be instrumental as we continue implementing our strategy which is to enable the most innovative companies bring new impactful treatments and therapies to market,” said Sander Slootweg, managing partner at Forbion.

In April, Forbion announced the hard close of its Forbion Growth 1 Fund which is focused on investing in late-stage life sciences companies.

Previously, Bos worked at the Netherlands Vaccine Institute, the Dutch National Institute of Public Health and in private equity. He holds a PhD in pharmacy from the University of Groningen.